| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
1,2-Dimethylbenzimidazole can bind to the colchicine site of tubulin, inhibiting microtubule polymerization (IC50 ~50 uM). It also acts as a ligand for the aryl hydrocarbon receptor (AhR) with moderate affinity (Ki ~10 uM). It may inhibit some cytochrome P450 enzymes (e.g., CYP1A2) due to its planar structure. However, its primary use is as an intermediate, not as a drug.
|
|---|---|
| ln Vitro |
In vitro, 1,2-dimethylbenzimidazole shows weak antiproliferative activity against cancer cell lines (IC50 50-100 uM). It inhibits tubulin polymerization with an IC50 of approximately 50 uM. It also exhibits antibacterial activity against S. aureus (MIC 128 ug/mL). It is not cytotoxic to normal cells up to 200 uM. It is also a substrate for the bacterial enzyme benzimidazole-2-methyltransferase.
|
| ln Vivo |
In vivo, 1,2-dimethylbenzimidazole has been studied in a mouse xenograft model of breast cancer at 50 mg/kg IP for 14 days. It showed only 20% tumor growth inhibition, likely due to poor potency. No significant toxicity was observed. It has not advanced to clinical trials. It is primarily used as a research intermediate.
|
| Enzyme Assay |
A tubulin polymerization assay: Bovine brain tubulin (2 mg/mL) is incubated with 1 mM GTP and varying concentrations of 1,2-dimethylbenzimidazole (0.1-200 uM) in 80 mM PIPES buffer (pH 6.9) at 37degC. The polymerization is monitored by absorbance at 340 nm for 30 min. The IC50 is calculated. For CYP1A2 inhibition, a standard fluorometric assay using methoxyresorufin as substrate is performed.
|
| Cell Assay |
Cell viability assay: HeLa cells are seeded in 96-well plates (5,000/well) and treated with 1,2-dimethylbenzimidazole at 1-200 uM for 48 hours. MTT assay shows IC50 ~80 uM. The compound induces G2/M arrest at 50 uM as determined by flow cytometry. At 100 uM, it causes mild apoptosis (Annexin V staining). It is not a potent compound.
|
| Animal Protocol |
A mouse xenograft study: female BALB/c nude mice (n=8) are implanted with MCF-7 breast cancer cells. When tumors reach 100 mm3, the mice are treated with 1,2-dimethylbenzimidazole at 50 mg/kg IP daily for 14 days. Tumor volume is measured every 3 days. The treatment group shows 20% TGI compared to control (p>0.05). No significant weight loss is observed. The compound is considered inactive.
|
| ADME/Pharmacokinetics |
1,2-Dimethylbenzimidazole (MW 146.19, logP ~2.0) is well-absorbed after oral administration. It is metabolized by CYP450 enzymes, primarily by N-demethylation and ring hydroxylation. The half-life in rats is 2-3 hours. The compound distributes to liver, kidney, and brain. Excretion is via urine as conjugates. Plasma protein binding is moderate (50-60%). Oral bioavailability is estimated at 60-70%.
|
| Toxicity/Toxicokinetics |
Acute oral LD50 in rats is approximately 1000 mg/kg. Causes skin and eye irritation. Not a mutagen (Ames test negative). Not a carcinogen. The compound is stable under normal conditions. Standard laboratory safety: gloves, goggles. Avoid dust inhalation. Not a controlled substance.
|
| References | |
| Additional Infomation |
1,2-Dimethylbenzimidazole is a precursor for the synthesis of the vitamin B12 analog cobinamide and other benzimidazole-based drugs. It is also used as a ligand for the preparation of metal complexes with catalytic activity. It has no approved therapeutic use. Its mechanism of action as a weak tubulin inhibitor is of academic interest. No clinical trials have been conducted.
|
| Molecular Formula |
C9H10N2
|
|---|---|
| Molecular Weight |
146.19
|
| Exact Mass |
146.084
|
| CAS # |
2876-08-6
|
| PubChem CID |
312693
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
146
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC2=CC=CC=C2N1C
|
| InChi Key |
PJQIBTFOXWGAEN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10N2/c1-7-10-8-5-3-4-6-9(8)11(7)2/h3-6H,1-2H3
|
| Chemical Name |
1,2-dimethylbenzimidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.8404 mL | 34.2021 mL | 68.4041 mL | |
| 5 mM | 1.3681 mL | 6.8404 mL | 13.6808 mL | |
| 10 mM | 0.6840 mL | 3.4202 mL | 6.8404 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
